AGM 2024 - QUESTIONS, page-143

First 143 Last

Share
Profile

Follow
goldmad

1,045 Posts.

269

01/12/23

11:03

Post #: 71214406
Share

Originally posted by adherent: ↑

From my notes. Not exhaustive, and just for my own purposes. Corrections accepted as I may have misheard. But may be of interest.

Well that was a pretty good AGM. No violence, no casualties. Just some quick highlights from my notes.

Paul intends to relinquish the chair and become MD. No word on a replacement chair.

Confident of deals by Q2

China. Changes in regulatory means CFDA will accept applications on international trial data without China trials if there are enough ethnic Chinese in the study. We have 10% in our trials which is enough. CN registration does not require the drug be registered elsewhere. China can go first on that data. MRIs really started to drive CN interest.

OA deals in US and EU. Don’t want to push this too early bc an early deal before data is clear leaves too much on the table. So they are not yet going after these deals. But, they are nevertheless fielding incoming enquiries. Their preferred partners are likely from mid tier pharma rather than the biggest, because licensing requires whole of company attention and big pharma have tight bounds on therapeutic space and other attributes for their licensing. Mid tier are more nimble. They point out that mid tier pharma are still very big companies.

Regional MPS. Don’t expect big up front numbers but the back end can be very big.

Paused development of auto injector due to cash. Right choice.

No one thinks it’s likely the FDA will ask us to repeat early 1.5mg dose safety trials with our 2mg Phase III dose. I think this is quite unlikely. Generally good feeling in the room although Paul laments the share price.

I had a good long chat with Paul afterwards about mechanisms of actions which was really interesting. my wife grabbed their BDM to talk about the difficulties of retaining your ip in China. A good experience. We still have a way to go to get out from underwater though.

I love Melbourne in summer. Cold windy and raining. Italian cafés do go a long way to making up for it though.

Expand

Hi Adherent

Are you able to say what Paradigms thoughts were in relation to IP in China?
Cheers

PAR Price at posting: 39.0¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AI stocks: What to expect in 2024-25

There are more pages in this discussion • 9 more messages in this thread...

First 143 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 30.5¢		Change 0.005(1.67%)		Mkt cap ! $106.6M

Open	High	Low	Value	Volume
30.5¢	31.5¢	29.5¢	$152.7K	501.9K

Buyers (Bids)

No.	Vol.	Price($)
2	16864	30.5¢

Sellers (Offers)

Price($)	Vol.	No.
31.5¢	20426	2

View Market Depth

No.	Vol.	Price($)
2	16864	0.305
1	62640	0.300
4	99959	0.295
5	18241	0.290
3	51043	0.285

Price($)	Vol.	No.
0.315	20426	2
0.320	55000	2
0.325	50366	4
0.330	56660	4
0.335	13500	2

Last trade - 16.10pm 17/07/2024 (20 minute delay)

PAR (ASX) Chart

AGM 2024 - QUESTIONS, page-143

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AI stocks: What to expect in 2024-25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

AGM 2024 - QUESTIONS, page-143

Top Stories

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AI stocks: What to expect in 2024-25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News